Hyperfine, Inc.
HYPR · XNASCIK 1833769fmd_012RX5WW55VY0EQ743K5NB4DRYManufacturing · Electromedical & Electrotherapeutic ApparatusTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 24 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 0 | 1 | 7 | 11 | 13 | 14 |
| Cost of revenue | 1 | 3 | 6 | 6 | 7 | 7 |
| Gross profit | (0) | (1) | 1 | 5 | 6 | 7 |
| Research and development | 15 | 26 | 28 | 22 | 22 | 17 |
| Selling, general and administrative | 8 | 38 | 47 | 30 | 27 | 26 |
| Total operating expenses | 23 | 64 | 75 | 53 | 49 | 44 |
| Operating income | (23) | (65) | (74) | (48) | (43) | (37) |
| Interest and investment income | 0 | 0 | 1 | 4 | 2 | 1 |
| Other non-operating income (expense) | (0) | (0) | (0) | 0 | 0 | (0) |
| Income before taxes | (23) | (65) | (73) | (44) | (41) | (36) |
| Income tax expense | – | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | (65) | (73) | (44) | (41) | (36) |
| Net income | (23) | (65) | (44) | (44) | (41) | (36) |
| Net income to common shareholders | (23) | (65) | (73) | (44) | (41) | (36) |